Vabysmo
Chemical Name | faricimab-svoa |
Dosage Form | Injection (intravitreal; 120 mg/Ml) |
Drug Class | Inhibitors |
System | Ocular |
Company | Genentech |
Approval Year | 2022 |
Indication
- For the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (nAMD)
- For the treatment of patients with Diabetic Macular Edema (DME)